Details for Patent: 7,732,490

Title:	Methods of treating cancer
Abstract:	The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.
Inventor(s):	Richon; Victoria M. (Rye, NY), Chiao; Judy H. (Berkeley Heights, NJ), Kelly; William Kevin (Scotch Plains, NJ), Miller; Thomas A. (Brookline, MA)
Assignee:	Merck HDAC Research, LLC (Boston, MA) Sloan-Kettering Institute for Cancer Research (New York, NY)
Filing Date:	Sep 11, 2007
Application Number:	11/853,700
Claims:	1. A method of treating lung cancer in a patient, comprising orally administering a single therapeutically effective dose of up to 400 mg of suberoylanilide hydroxamic acid (SAHA) represented by the following structure: ##STR00062## or a pharmaceutically acceptable salt or hydrate thereof. 2. The method of claim 1, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 200 mg daily. 3. The method of claim 1, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 400 mg daily. 4. A method of treating Non-Hodgkins lymphoma in a patient, comprising orally administering 200 mg twice daily of suberoylanilide hydroxamic acid (SAHA) represented by the following structure: ##STR00063## or a pharmaceutically acceptable salt or hydrate thereof. 5. A method of treating myeloma in a patient, comprising orally administering a single therapeutically effective dose of up to 400 mg of suberoylanilide hydroxamic acid (SAHA) represented by the following structure: ##STR00064## or a pharmaceutically acceptable salt or hydrate thereof. 6. The method of claim 5, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 200 mg daily. 7. The method of claim 5, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 400 mg daily. 8. A method of treating breast carcinoma in a patient, comprising orally administering a single therapeutically effective dose of up to 400 mg of suberoylanilide hydroxamic acid (SAHA) represented by the following structure: ##STR00065## or a pharmaceutically acceptable salt or hydrate thereof. 9. The method of claim 8, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 200 mg daily. 10. The method of claim 8, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 400 mg daily. 11. A method of treating ovarian carcinoma in a patient, comprising orally administering a single therapeutically effective dose of up to 400 mg of suberoylanilide hydroxamic acid (SAHA) represented by the following structure: ##STR00066## or a pharmaceutically acceptable salt or hydrate thereof. 12. The method of claim 11, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 200 mg daily. 13. The method of claim 11, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 400 mg daily. 14. A method of treating cancer selected from the group consisting of colorectal carcinoma, Hodgkins lymphoma, bladder melanoma, renal carcinoma and prostate carcinoma in a patient, comprising orally administering a single therapeutically effective dose of up to 400 mg of suberoylanilide hydroxamic acid (SAHA) represented by the following structure: ##STR00067## or a pharmaceutically acceptable salt or hydrate thereof. 15. The method of claim 14, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 200 mg daily. 16. The method of claim 14, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 400 mg daily. 17. The method of claim 1, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 18. The method of claim 2, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 19. The method of claim 3, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 20. The method of claim 4, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 21. The method of claim 5, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 22. The method of claim 6, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 23. The method of claim 7, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 24. The method of claim 8, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 25. The method of claim 9, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 26. The method of claim 10, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 27. The method of claim 11, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 28. The method of claim 12, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 29. The method of claim 13, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 30. The method of claim 14, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 31. The method of claim 15, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 32. The method of claim 16, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 33. A method of treating cancer in a patient, comprising orally administering a single therapeutically effective dose of up to 400 mg of suberoylanilide hydroxamic acid (SAHA) represented by the following structure: ##STR00068## or a pharmaceutically acceptable salt or hydrate thereof. 34. The method of claim 33, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 200 mg daily. 35. The method of claim 33, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 400 mg daily. 36. The method of claim 33, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 37. The method of claim 34, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 38. The method of claim 35, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 39. The method of claim 1, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered daily. 40. The method of claim 1, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 200 mg. 41. The method of claim 1, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 400 mg. 42. The method of claim 39, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 43. The method of claim 40, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 44. The method of claim 41, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 45. The method of claim 5, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered daily. 46. The method of claim 5, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 200 mg. 47. The method of claim 5, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 400 mg. 48. The method of claim 45, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 49. The method of claim 46, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 50. The method of claim 47, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 51. The method of claim 8, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered daily. 52. The method of claim 8, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 200 mg. 53. The method of claim 8, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 400 mg. 54. The method of claim 51, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 55. The method of claim 52, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 56. The method of claim 53, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 57. The method of claim 11, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered daily. 58. The method of claim 11, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 200 mg. 59. The method of claim 11, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 400 mg. 60. The method of claim 57, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 61. The method of claim 58, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 62. The method of claim 59, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 63. The method of claim 14, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered daily. 64. The method of claim 14, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 200 mg. 65. The method of claim 14, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 400 mg. 66. The method of claim 63, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 67. The method of claim 64, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 68. The method of claim 65, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 69. The method of claim 33, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered daily. 70. The method of claim 33, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 200 mg. 71. The method of claim 33, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is orally administered as a single dose of 400 mg. 72. The method of claim 33, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 73. The method of claim 70, wherein suberoylanilide hydroxamic acid (SAHA) is administered. 74. The method of claim 71, wherein suberoylanilide hydroxamic acid (SAHA) is administered.